Moderna Inc (NASDAQ:MRNA) price on Thursday, April 10, fall -8.14% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $24.50.
A look at the stock’s price movement, the close in the last trading session was $26.67, moving within a range at $23.7 and $25.9. The beta value (5-Year monthly) was 2.233. Turning to its 52-week performance, $170.47 and $23.15 were the 52-week high and 52-week low respectively. Overall, MRNA moved -30.02% over the past month.
Moderna Inc’s market cap currently stands at around $9.45 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-13.
Analysts have a consensus estimate of 130.35M for the company’s revenue for the quarter, with a low and high estimate of 83M and 183M respectively. The average forecast suggests down to a -21.95% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 2.17B, representing a -33.03% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that MRNA is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
17 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 12 recommend MRNA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 2 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
MRNA’s current price about -18.31% and -24.33% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 33.42, while 7-day volatility ratio is 12.11% and 7.32% in the 30-day chart. Further, Moderna Inc (MRNA) has a beta value of 2.00, and an average true range (ATR) of 2.48. Analysts have given the company’s stock an average 52-week price target of $55, forecast between a low of $45 and high of $69. Looking at the price targets, the low is -83.67% off current price level while to achieve the yearly target high, price needs to move -181.63%. Nonetheless, investors will most likely welcome a -124.49% jump to $55 which is the analysts’ median price.
If we refocus on Moderna Inc (NASDAQ:MRNA), historical trading data shows that trading volumes averaged 12.64 over the past 10 days and 11.79 million over the past 3 months. The company’s latest data on shares outstanding shows there are 386.00 million shares.
The 11.44% of Moderna Inc’s shares are in the hands of company insiders while institutional holders own 70.77% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 46.88 million on 2025-03-14, giving us a short ratio of 3.8. The data shows that as of 2025-03-14 short interest in Moderna Inc (MRNA) stood at 1684.0 of shares outstanding, with shares short rising to 42.3 million registered in 2025-02-14. Current price change has pushed the stock -41.08% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the MRNA stock continues to rise going into the next quarter.
